ANNEX

to Decision of the Eurasian Economic Commission’s Council
No. dated
, 20

AMENDMENTS
introduced to Decision No. 78 of the Eurasian Economic Commission's Council dated November 3, 2016

1. In paragraph 2:

(a) Subparagraph “d”, paragraph 2, after the words “December 31, 2025”, the wording “in accordance with the procedure established in Section XIII of the Rules” shall be added;

(b) Subparagraph “e” shall read as follows:

"(e) The certificates of marketing authorization for medicinal products granted in accordance with the legislation of Member States are valid until the expiry of their validity period specified in subparagraph “c” of this paragraph, except for the validity period of the certificates of marketing authorization in respect of which statements have been submitted to the authorized authority (expert organization) of the reference Member State until December 31, 2025 regarding harmonization of the Marketing Authorization Applications, approved in accordance with the Rules of the Member State, with the requirements of the Union pursuant to the procedure established in Section XIII of these Rules, the validity period of which is established in accordance with subparagraph “f” of this paragraph;";

(d) add subparagraphs "f" and "g" that read as follows:

"(f) the validity of the certificates of marketing authorization for the medicinal products, applied for harmonization with the Union's requirements and not having completed the said procedure as of December 31, 2025 in the reference Member State, shall be extended for the period of the procedure set out in Section XIII of the Rules, but not more than 3 years in each of the claimed Member States from the date of submission of the application in the reference Member State, and additionally for the period of the said procedure in the Member State concerned, but not more than 2 years from the date of submission of the application in the Member State concerned. Moreover, the application to the reference Member State shall be submitted no later than the date of expiry of the 3-year period from the date of submission of the application in the reference Member State.

The validity of the certificates of marketing authorization for the medicinal products that completed the harmonization procedure as of December 31, 2025 in the reference Member State shall be extended for the period of procedure implementation in the claimed Member States concerned, but not more than 2 years from December 31, 2025;

(g) in the registers of medicinal products of the Member States, authorized authorities (organizations) are entitled to indicate information on the registration status of a medicinal product taking into account the provisions of the Rules on its prolongation.".

2. In the Rules for Marketing Authorization and Expert Examination of Medicinal Products for Human Use approved by the mentioned Decision:

a) Indent 6 of paragraph 66 shall read as follows:

"The Applicant shall have the right to initiate the amendment procedure in the reference Member State in accordance with Annex No. 19 to these Rules before the date of completion of the registration procedure in the Member States concerned, where the procedure has been initiated. In these cases, after

completion of the registration procedure in the Member State concerned, the Applicant shall submit to the authorized authority (expert organization) of the Member State concerned the applications regarding making amendments approved by the reference Member State.";

b) The first sentence of indent 1 of paragraph 66^1 should be completed with the words “and in the mutual recognition procedure in the Member State(s) concerned”.

c) In paragraph 126, the words "140 working days" shall be replaced by the words "260 working days";

d) Indent 3 of paragraph 147 shall read as follows:

"Any variations to the Marketing Authorization Application are allowed before and during the recognition procedure in the claimed Member State(s) concerned in accordance with paragraphs 66 and 66^1 of these Rules, provided the medicinal product has been approved under the mutual recognition procedure in the reference Member State”;

e) In paragraph 164, the word “States” shall be followed with “in accordance with the procedure established in Section XIII of these Rules”;

f) The last indent of paragraph 165 shall read as follows:

“In the Member States, the marketing of medicinal products, the validity of certificates of marketing authorization of which has been extended for the period until the end of harmonization in each of the Member States in accordance with the provisions of paragraph 2, subparagraph "f" of the Council's Decision, shall be allowed until the expiration date (shelf life) of these medicinal products.”;

g) Paragraph 170 shall read as follows:

"170. An application for harmonization of the Marketing Authorization Application for a medicinal product approved in the Member States, according to their legislation, with the requirements of the Union shall be submitted to

the authorized authority (expert organization) of the reference Member State until December 31, 2025.

The authorized authority (expert organization) of the reference Member State shall communicate within 5 working days the authorized authorities (expert organizations) of the Member State(s), specified in the application for harmonization of the Marketing Authorization Application with the requirements of the Union as the Member State(s) concerned, on any applications submitted as of December 31, 2025 and subsequently of the decisions taken during the period of the mentioned procedure.

In case of refusal to harmonize the Marketing Authorization Application with the requirements of the Union or in case of withdrawal by the Applicant of the application for harmonization in the reference Member State, the Applicant shall notify the authorized authorities (expert organizations) of the Member State(s) concerned, specified in the application, about further intentions with regard to the Marketing Authorization Application for the medicinal product.

During the procedure of harmonization, the validity of the certificate of marketing authorization for the medicinal product granted in accordance with the legislation of the Member State, where the Application is submitted, as well as in the Member State(s) specified in the Application in the form of Annex No. 2 to these Rules in the column titled "Other Member States of the Eurasian Economic Union for the application submission (if any)" (including under the procedure of introducing variations to the Marketing Authorization Application for the medicinal product in accordance with Annex No. 19 to these Rules), shall be extended for the periods provided for by subparagraph “f”, paragraph 2 of Decision No. 78 of the Eurasian Economic Commission's Council dated November 3, 2016, On Rules for Marketing Authorization and Expert Examination of Medicinal Products for Human Use, in each of the

Member States where this medicinal product has been registered in accordance with the legislation of the relevant Member State (hereinafter, the Council Decision).";

h) Paragraph 172:

Indent 3 shall read as follows:

"Variations are allowed to be made by the Applicant according to the procedure in Annex No. 19 to these Rules, at the end of the harmonization of the Marketing Authorization Application with the Union's requirements in the reference Member State before or after the initiation of the mutual recognition procedure in the Member State(s) concerned (before or after the submission of the relevant application to the authorized authority (expert organization) of the Member State(s) concerned).";

shall be supplemented by the following indents:

"In these cases, after completion of the recognition procedure in the State of recognition, the Applicant shall submit to the authorized authority (expert organization) of the Member State concerned an application for introducing variations that were not made to the Marketing Authorization Application in the reference Member State prior to the initiation of the recognition procedure in the Member State(s) concerned.

Upon coordination with the authorized authority (expert organization) of the Member State concerned, the Applicant is entitled to apply for variations that were not made to the Marketing Authorization Application in the reference Member State during the recognition procedure in the Member State(s) concerned.";

i) Indent 2 of paragraph 174 shall be deleted;

j) Paragraph 180:

indent 1 shall read as follows:

"180. If an expert examination of the medicinal product performed by the authorized authority of the reference Member State resulted in a favorable conclusion regarding the compliance of the Marketing Authorization Application for the medicinal product with the requirements of these Rules, the authorized authority of the reference Member State within a period of up to 10 working days shall: grant the certificate of marketing authorization for the medicinal product to the Applicant in accordance with the form in Annex No. 17 to these Rules, issue approved SmPC, patient leaflet, product specification file, packaging mock-ups, the assessment report (if required, the Applicant shall be issued approved SmPC, patient leaflet and packaging mock-ups of the medicinal product developed in the official language of the reference Member State), a summary of the coordinated risk management plan (if required) and enter information on the medicinal product registration into the unified register.";

Indent 3 shall read as follows:

"After harmonization of the Marketing Authorization Application for the medicinal product with the Union's requirements, the manufacture the medicinal product shall be allowed in the Member State(s) and third countries, provided for the availability of the certificate of marketing authorization for the medicinal product granted in accordance with the legislation of the Member State, within 180 calendar days from the date of harmonization of the Marketing Authorization Application for the medicinal product with the Union's requirements (the date specified in the certificate of marketing authorization for the medicinal product shall be deemed to be the date of completion of the harmonization procedure in each individual Member State listed in the application under paragraph 170 of these Rules).";

Indent 3 shall be followed by the following indent:

"During the procedure of harmonization with the Union's requirements,

the circulation of the medicinal product is allowed, provided for the availability of the certificate of marketing authorization for the medicinal product granted in accordance with the legislation of the Member State.".

k) (a) In the last indent, paragraph 184, after the words “December 31, 2025”, the wording “in accordance with the procedure established in Section XIII of these Rules” shall be added;

l) Paragraph 185 shall read as follows:

"185. The confirmation (renewal) of the marketing authorization and variations to the Marketing Authorization Application of the medicinal product, registered in the Member State(s) in accordance with their legislation and which has not passed the procedure for harmonization with the Union's requirements under Section XIII of these Rules, shall be implemented in accordance with the legislation of the Member State(s) until December 31, 2025. If an application for harmonization with the Union's requirements is submitted in the reference Member State, in accordance with the procedure established in Section XIII of these Rules until December 31, 2025, variations to the Marketing Authorization Application of such medicinal products, generated in accordance with the legislation of the Member State(s), shall be made in accordance with the legislation of the Member State(s) until the expiration of the validity of such certificates of the Marketing Authorization Application, specified in subparagraph “f”, paragraph 2 of the Council Decision.”;

m) Indent 2, paragraph 186 shall read as follows:

“Marketing of medicinal products released into circulation in the territory of a Member State is allowed during the procedure of harmonization with the Union's requirements, based on the certificate of marketing authorization for the medicinal product granted in accordance with the legislation of the Member State and/or relevant information specified in the

registers of the Member States.”.

3. Annex No. 19 to these Rules:

(a) shall be supplemented with paragraph 2.5 with the following wording:

"2.5 A procedure for making new variations before completing the review of the Marketing Authorization Application for a medicinal product in the Member State(s) concerned

2.5.1. When the Applicant initiates a non-significant type-IA and/or type-IA_{IN} variation in the reference Member State before the recognition procedure has been completed in the Member State(s) concerned and approved by the authorized authority (expert organization) of the reference Member State during the recognition procedure, after completion of this procedure, the Applicant shall submit to the authorized authority (expert organization) of the Member State concerned an application, documents confirming payment of the fee (duty) for variations made to the marketing authorization application in cases and in the procedure determined as per legislation of the Member State(s), and, if required, the documents contained in Module 1 of the marketing authorization application, specific to the Member State concerned, relevant to the variations being introduced, as well as a copy of the resolution of the authorized authority (expert organization) regarding the feasibility of attaching the relevant versions (sequences) to the electronic marketing authorization application, or approving the variations.

When a variation is made that does not result in revision of the medicinal product information in accordance with paragraph 1.6 of this annex or does not affect the information contained in the unified register, the authorized authority (expert organization) of the Member State concerned shall attach the relevant version (sequence) to the electronic marketing authorization application and update the information in the unified register.

When a variation is made that do result in revision of the medicinal product information in accordance with paragraph 1.6 of this annex, the authorized authority (expert organization) of the Member State concerned shall submit an application to the authorized authority (expert organization) of the reference Member State to provide access to the version (sequence) of the electronic marketing authorization application under the submission for making variations, by means of the integrated system. The authorized authority (expert organization) of the reference Member State shall provide this access within up to 5 working days from the date of receipt of the application.

After receiving this access, the authorized authority (expert organization) of the Member State concerned shall conduct in accordance with indents 3-5, paragraph 2.1.4 of this Annex.

2.5.2. When the Applicant initiates a significant type-IB variation and type-II variation in the reference Member State before the recognition procedure has been completed in the Member State(s) concerned and approved by the authorized authority (expert organization) of the reference Member State during the recognition procedure, after completion of this procedure, the Applicant shall submit to the authorized authority (expert organization) of the Member State concerned an application, documents confirming payment of the fee (duty) for variations made to the marketing authorization application in cases and in the procedure determined as per legislation of the Member State(s), and, if required, the documents contained in Module 1 of the marketing authorization application, specific to the Member State concerned, relevant to the variations being introduced, as well as a copy of the resolution of the authorized authority (expert organization) on the approval of the variations and/or a document confirming the validity of the presented version (consequence) of the electronic marketing authorization application,

containing country-specific documents of Module 1 of the marketing authorization application.

The authorized authority (expert organization) of the Member State concerned shall submit an application to the authorized authority (expert organization) of the reference Member State to provide access to the version (sequence) of the electronic marketing authorization application under the submission for making variations, by means of the integrated system. The authorized authority (expert organization) of the reference Member State shall provide this access within up to 5 working days from the date of receipt of the application.

The Member State concerned shall make a decision on approval or refusal of the application for a type-IB variation or type-II variation and communicate the Applicant by email within a period of up to 20 working days from the date of receipt of the submission for variations and documents from the Applicant specified in indent 1 of paragraph 2.5.2 of the Rules for Marketing Authorization and Expert Examination, as well as for access to the materials of the marketing authorization application. If required, no later than 15 working days after receiving access to the assessment report, the authorized authority (expert organization) of the Member State concerned shall submit an application to the Applicant and to the authorized authority (expert organization) of the reference Member State in accordance with the form in Annex No. 18 to these Rules.

The Applicant shall send a response to the application to the authorized authority (expert organization) of the Member State concerned within a period of up to 90 working days from the date of receipt of the mentioned application from the authorized authority (expert organization) of the last of the Member State concerned. The time required for the Applicant to respond to the application shall not be included in the total time for the procedure

implementation. Within up to 5 business days from the date of the Applicant's response, the authorized authority (expert organization) of the Member State concerned shall grant an access to it to the authorized authority (expert organization) of the reference Member State via the Integrated System.

If a favorable opinion is granted, within a period of up to 5 working days from the date of its adoption, the authorized authorities (expert organizations) of the Member States concerned shall enter the relevant information in the unified register, if required, along with the attachment of modified approved Summary of product characteristics, patient leaflet, packaging mock-ups, product specification file, in accordance with the procedure established for development and maintenance of the unified register; they shall also issue to the Applicant the modified Summary of product characteristics, patient leaflet, packaging mock-ups, product specification file, and, if required, certificate of the marketing authorization.".

4. Annex No. 16 to the mentioned Rules shall read as follows:

“Annex No. 16

to the Rules for Marketing Authorization
and Expert Examination of Medicinal
Products for Human Use

A FORM OF ASSESSMENT REPORT ON THE SAFETY, EFFICACY, AND QUALITY

(form)

Name of the expert organization of the Eurasian Economic Union Member State

APPROVED BY

[position and full name of the Head of
the expert organization]

_____
(signature)

dd. DD.MM.YYYY

L.S.

THE ASSESSMENT REPORT
ON THE SAFETY, EFFICACY, AND QUALITY

[Brand name]

[Dosage form and strength(s)]

_____
(INN (if available) or common (generic) or chemical name)

Application No. _____ date _____

Applicant: _____

Date of Report _____

TITLE PAGE

Brand name of the medicinal product in the reference Member State and in the Member State(s) concerned (if different)	
INN (if available) or common (generic) or chemical name of the active substance	
Pharmacotherapeutic group (ATC Code)	
Dosage form, strength(s) and presentation(s)	
Reference Member State	
Name and address of the Marketing Authorization Holder in the reference Member State	

Authorization number and date of the certificate of Marketing Authorization granted by the reference Member State	
Date and number of the first Marketing Authorization granted by the reference Member State	
Member State(s) concerned	
Name and address of the Marketing Authorization Holder in the Member State(s) concerned	
Information on registration in the Member State(s) concerned specified in the application[1]	
Authorization number(s) and date(s) of the certificate(s) of Marketing Authorization granted by the Member State(s) concerned (if any)[2]	
Name and address of the manufacturer of the medicinal product (all production sites involved in the manufacturing process of the medicinal product (including solvents) with indication of the stages of the production process), including those conducting release quality control (batch release)	

1. To be filled in when the report is first issued.
2. To be filled in as part of updating when variations requiring expert examination are made.

The information on the title page is updated when changes affecting the information contained therein are made.

When updating the assessment report, the title page (if required), the List of Procedures section and the relevant annex shall be completed.

Sections requiring updating are to be completed in the relevant annex.

List of procedures

(making variations, confirmation (renewal) of the marketing authorization submitted to the reference Member State after authorization of a medicinal product, or harmonization of the Marketing Authorization Application for the medicinal product with the requirements of the Union

Application identification number, version of the Marketing Authorization Application	Name, type and summary of the variations being made or information on confirmation of marketing authorization	Opinion (favorable / unfavorable)	Number of the Annex containing updated parts of the assessment report

The table is to be filled throughout the life cycle of the medicinal product.

I. Executive Summary

The assessment report has been generated in accordance with the provisions of <paragraph 60>, <paragraph 178> of the Rules for Marketing Authorization and Expert Examination of Medicinal Products for Human Use approved by Decision No. 78 of the Eurasian Economic Commission's Council dated November 3, 2016 (hereinafter, the Rules for Marketing Authorization and Assessment) based on the results of the examination of the documents contained in the Marketing Authorization Application for the medicinal product for the purposes of the Marketing Authorization granted under the mutual recognition procedure / *the Marketing Authorization granted under the decentralized procedure / harmonization of the Marketing Authorization with the requirements of the Union with concurrent variations made to the Marketing Authorization* under Application(s) No. _____ dated _____ .

II.1. Medicinal Product information

II.1.1. Mechanism of action

II.1.2. Pharmacological classification

II.1.3. Claimed indications and recommendations for use

<(including the management strategy for a potential risk) and strength>

II.1.4. Special pharmacological aspects

<(if any) (e.g., new route of administration etc.)>

II.2 Overview on the submitted Marketing Authorization Application for the medicinal product

As of the date of approval of this report, 000n is the current version (sequence) of the marketing authorization application.

The marketing authorization application contains Modules 1 to 5 (1 to 3).

<Specify whether an active substance is/is not considered a novel active substance.>

<For applications submitted under Sections 14.4 and 15.2 of Annex No. 1 to the Rules for Marketing Authorization and Assessment (simplified Marketing Authorization Application), in this section, a document of Module 1.5.1 shall be submitted summarizing any reasons and data used to demonstrate that the use of the substance(s) contained in the medicinal product is well established and has an acceptable level of safety and recognized efficacy. A clear scientific justification shall be provided for the suitability of refusing to conduct certain studies.>

<For applications submitted for generic medicinal products, in this section, a document of Module 1.5.2 of the Marketing Authorization Application should be submitted summarizing the facts and reasons demonstrating that the medicinal product is almost equivalent to the approved originator.>

<Specify whether the Applicant has submitted a Risk Management Plan (where applicable).>

<Submit the clinical drug development program and provide relevant comments in terms of proposed indications for use and posology (if applicable).>

<Specify whether scientific counseling has been conducted (if so, provide the date) and whether the applicant has complied the recommendations given to them.>

<Specify whether the Applicant has complied with the requirements of acts of the bodies of the Eurasian Economic Union (hereinafter, the Union) in the circulation of medicinal products.>

<Specify availability and/or need for drug development in terms of pediatric use and use in other special populations such as the elderly, males/females, and ethnic minorities.>

II.3. General notices on compliance with GMP, GLP, GCP, and harmonized ethical principles

II.3.1 The reference Member State has confirmed / has not confirmed compliance with the adopted standards of Good Manufacturing Practice (GMP) regarding this medicinal product at the sites involved in the production of the finished dosage form and release quality control (batch release).

Up-to-date information on the manufacturer's name and place of manufacture is provided on the title page of this report.

The Marketing Authorization Application contains the conclusion (certificate) _____ of the authorized authority of the reference Member State concerning compliance of the production site(s) performing the stages of the manufacture of the medicinal product with the requirements of Good Manufacturing Practice (GMP) No. _____ (date of issue _____, validity _____).

II.3.2 The documents and data submitted as part of the Marketing Authorization Application support /do not support the Applicant's compliance

with Good Laboratory Practice (GLP), Good Clinical Practice (GCP) and harmonized ethical principles.

II.3.3 No inspections on compliance with GMP, GLP, GCP and harmonized ethical principles are required.

III. Scientific review and discussion

<(the medicinal product) _____ is available in the dosage form of _____ containing _____ as an active substance>.

<The medicinal product is _____ (description of appearance). The medicinal product is available in _____ (description of primary and secondary packaging).>

III.1. Quality aspects

III.1.1. Active pharmaceutical ingredient (API)

Name of API, manufacturer, country of manufacture.

III.1.1.1 Chemical and pharmaceutical documentation and Quality overall summary for the API

<The chemical and pharmaceutical documentation and Quality Overall Summary for (the API) _____ manufactured by _____ are of acceptable quality in terms of the valid regulatory requirements.>

III.1.1.2. Manufacture and characterization of the API.

<Information on the API manufacturing process and its development is submitted; information on process validation of the API manufacture is provided. The materials submitted support the adequacy and reproducibility of the manufacturing process.

The structure of API has been confirmed by the methods: _____ . Information on the characterization of the active pharmaceutical ingredient has been provided, including data on related substances and potential synthesis impurities. The impurity profile has been considered acceptable>.

<For (the active pharmaceutical ingredient) _____ manufactured by _____ , a Certificate of Suitability with the European Pharmacopeia Monograph, CEP No. _____ issued by the European Directorate for the Quality of Medicines and Healthcare, has been submitted>

<The manufacturing process, in-process control, quality control of the API is carried out in accordance with validated procedures, which is supported by documents of the Restricted Part of the Active Pharmaceutical Ingredient Master File.>

III.1.1.3. Quality control of the API

<The parameters included in the Quality Control Specification for (the API) _____ are justified and meet compendial requirements; the data submitted regarding the API batch analysis support the consistency, homogeneity and specification compliance of the API quality and demonstrate that the proposed process technology of the API manufacture is consistent and controlled.>

<Validation of analytical procedures for quality control of the API has been performed to an appropriate extent.

III.1.1.4. API stability

<The re-test period for the production of (the API) _____ is justified by the data on API

stability studies and is _____ months (years) provided the API is stored in the proposed type of packaging.>

<According to the Certificate of Suitability with the European Pharmacopoeia for (the active pharmaceutical ingredient) _____, the European Directorate for the Quality of Medicines and Healthcare has established a re-test period of _____ months (years).>

III.1.2. Medicinal product

III.1.2.1. Assessment of pharmaceutical development aspects

<The pharmaceutical development of the medicinal product is adequately described, the choice of excipients is justified and their functions explained. The excipients and solvent components used are well characterized and of adequate pharmacopoeial quality. The packaging (closure) system is characterized and adequate, its compatibility with the components of the medicinal product has been demonstrated.>

<The medicinal product contains novel excipients.>

III.1.2.2 Assessment of production and in-process control data

<The description and flowchart of the manufacturing process of the medicinal product, data on the manufacturing process validation, description of control of critical stages of the intermediate product production, information on batch formulation have been submitted. The data provided demonstrate the consistency and homogeneity of the medicinal product batches.>

III.1.2.3. Medicinal Product Quality Control

<The medicinal product specifications cover appropriate parameters for this dosage form. Quality attributes and control methods (procedures) are sufficient to assess the quality of the medicinal product, are reproducible and meet current requirements. Data on the analytical procedure validation support their suitability for the medicinal product quality control. Reference standards

are used in accordance with their intended use in the medicinal product quality control.>

<Batch analysis has been performed on _____ batches of the medicinal product. According to the batch analysis results, the product meets the requirements of the proposed specification, which demonstrates the reproducibility of the production process, and batch to batch consistency and homogeneity of the product.>

<The quality of the medicinal product has been confirmed, including laboratory evaluation (testing) of samples for all quality parameters specified in the product specification file>.

<The medicinal product quality has been confirmed under the procedure of the state registration on the territory of _____ , including laboratory evaluation (testing) of samples of the medicinal product for all quality parameters specified in the product specification file>. The results of the tests performed have established that the procedures are reproducible, the samples of the medicinal product meet the requirements for the tested parameters. Quality requirements for the medicinal product have not changed since the date of registration on the territory of _____. Laboratory evaluation of the medicinal product samples is not required.>

III.1.2.4. Stability

<The conditions and stability study program comply with the Requirements for stability testing of medicinal products and pharmaceutical substances approved by Decision No. 69 of the Eurasian Economic Commission's Board dated May 10, 2018. The specifications include quality attributes that demonstrate an assessment of the properties of the medicinal product that are subject to changes during storage. The frequency of studies is sufficient to establish the stability profile of a medicinal product.>

<Specify whether the Applicant submitted complete study data or a commitment to complete the stability study in the post-approval period.>

<The proposed shelf life of <number> months if stored at <specify the storage conditions> for the medicinal product is considered acceptable.>

III.1.2.5 General conclusion on the medicinal product quality aspects

<Module 3 submitted covers all quality aspects of the active pharmaceutical ingredients and the medicinal product. The information provided suggests a conclusion about the controlled quality of active pharmaceutical ingredients and the medicinal product throughout the established expiration date (shelf life).>

III.2. Non-clinical aspects

III.2.1. Pharmacology

III.2.2. Pharmacokinetics

III.2.3. Toxicology

III.2.3.1 Toxicity for single administration (acute toxicity)

III.2.3.2. Toxicity for repeated (multiple) administration (subchronic, chronic toxicity)

III.2.3.3. Genotoxicity

III.2.3.4. Carcinogenicity

III.2.3.5. Reproductive and developmental toxicity

III.2.3.6. Local tolerance

III.2.3.7. Other toxicology studies (antigenicity, immunotoxicity, etc.)

III.2.3.8 Evaluation of the designer's interpretation of the results of non-clinical studies (pharmacology, pharmacokinetic, toxicology studies) of the medicinal product

III.3. Clinical aspects

III.3.1. Pharmacokinetics

III.3.2. Pharmacodynamics

III.3.3. Clinical efficacy

III.3.4. Clinical safety

III.3.5. Pharmacovigilance system

<The Applicant (the presumed future Marketing Authorization Holder) submitted a signed explanatory memorandum on the pharmacovigilance system of the Applicant (the presumed future Marketing Authorization Holder). The reference Member State considers the explanatory memorandum acceptable, provided that the pharmacovigilance system dossier fully complies with the requirements stipulated in the Good Pharmacovigilance Practice module.>

III.3.6. Risk management plan

<The results of the risk management plan evaluation shall be provided if its submission is essential in view of the provisions of the Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union, approved by Decision No. 87 of the Eurasian Economic Commission's Council dated November 3, 2016, or an indication of its non-submission with references to the acts of the Union's bodies in the circulation of medicinal products.>

III.3.7. Periodic safety update report

<The Marketing Authorization Holder shall submit the first periodic safety update report for this medicinal product within {xx} months after its approval.

Thereafter, the Marketing Authorization Holder shall submit periodic safety update reports for this medicinal product.>

IV. Risk-benefit assessment

<Summarize the main findings and evaluation questions (detailed information shall be provided in the main sections on quality, efficacy and safety, respectively). Integrate these aspects when considering benefit-risk ratios for specific populations.

Include non-clinical and clinical safety data, post-approval commitments, and consider any aspects of risk management that may influence the risk-benefit assessment.

The risk-benefit assessment shall also include the following aspects, if applicable (taken from the Marketing Authorization Application in a Common Technical Document format):

1. Compliance with the requirements of acts of the Union's bodies in the circulation of medicinal products and the Expert Committee for Medicinal Products.

2. Dose ranging and posology.

3. Safety and efficacy in subpopulations (e.g., for patients of a particular age, sex, race, body organ function, disease severity, and genetic polymorphism).

4. Known and potential mechanisms of drug-drug interactions.

5. Safety signals relevant to, for example, carcinogenic effects, teratogenic effects, prolongation of the QT interval or suspected hepatotoxicity.

6. Use of surrogate endpoints to evaluate efficacy of action when drug toxicity is significant.

7. Verification of all safety issues addressed in the pharmacovigilance plan (if submitted).

8. Safe and/or effective use of a medicinal product implies potential challenges in selecting risk management approaches involving specialized medical expertise or patient education.

9. Verification of the Applicant's consideration of risks and ambiguities based on: conditions of granting the marketing authorization, composition of information about the product, follow-up control measures or risk management plan.

10. Verification of availability of sufficient information to characterize the benefit-risk of the medicinal product compared to an appropriately established treatment regimen (if available). Subject to review in the appropriate order.

In addition, data on pediatric use of the drug product or any development plans for pediatric use should be reviewed.

If appropriate, this section should include information and data on bioequivalence assessments for applications for generic medicinal products submitted for authorization. The accuracy (correctness) of the selection of the reference drug should be reflected in the conclusion.

V. Recommended Conditions for Marketing Authorization and Product Information

V.1. Conditions of granting the Marketing Authorization

Based on the results of the expert examination of the Marketing Authorization Application for the medicinal product under the procedure of _____ , the Applicant may/may not be granted the Marketing Authorization <valid for 5 years / permanent / No. _____ dated _____.>.

Legal status

Prescription status of the medicinal product: no prescription / prescription only / for medical and preventive treatment facilities

Follow-up measures

<Includes information on the commitments by the Applicant regarding the information contained in the marketing authorization application, which are subject to control by the Applicant and require making variations to the marketing authorization application in the post-approval period but not later than the planned re-approval of the medicinal product.

Special commitments

This section should specify the conditions for granting a marketing authorization (if applicable).

V.2. Summary of product characteristics

V.3 Patient leaflet (package leaflet) and user testing

V.3.1 Patient leaflet (package leaflet)

V.3.2. Evaluation of user testing

<The result of the user testing evaluation shall be presented.

Or

<No submission of the results of user testing of the patient leaflet (package leaflet) (hereinafter, PL) is required.

There was no evaluation of the PL user testing. The Applicant has provided in the Marketing Authorization Application a sufficient justification regarding the absence of the need for user testing, recognized as acceptable by the reference Member State.>

V.4. Labeling and packaging mock-ups

The labeling on the package of the medicinal product complies with the Requirements for the Labelling of Medicinal Products for Human Use and Veterinary Medicinal Products approved by Decision No. 76 of the Eurasian Economic Commission's Council dated November 3, 2016.

VI. Conclusion

Based on the results of expert examination of data on quality, safety, efficacy and benefit-risk of the medicinal product under the Application No. _____ dated _____ , *it is advised / not advised* to approve human use of the medicinal product in accordance with the procedure established by the Rules for Marketing Authorization and Expert Examination of Medicinal Products for Human Use approved by Decision No. 78 of the Eurasian Economic Commission's Council dated November 3, 2016.

ANNEX FORM CONTAINING UPDATED PARTS OF THE ASSESSMENT REPORT

(*Sections that require updating are to be completed)*

Annex No. X to the Assessment Report on the Safety, Efficacy and Quality
(Application(s) No. _____
dated _____)

I. Executive Summary

The Assessment Report has been updated in accordance with the provisions of paragraph 152 of the Rules for Marketing Authorization and Expert Examination of Medicinal Products for Human Use approved by Decision No. 78 of the Eurasian Economic Commission's Council dated November 3, 2016, based on the results of the examination of documents contained in the Marketing Authorization Application for a medicinal product for human use for the purpose of making variations to the Marketing Authorization Application of the medicinal product under Application No. _____ dated _____.

<Variations made to the Marketing Authorization Application for a medicinal product <*shall include*>/<*shall not include*> revision of the medicinal product information (product specification file, SmPC, active substance, packaging mock-ups).>

Variations made to the Marketing Authorization Application for a medicinal product:

Code	Type	Brief description of the variation

II.1. Medicinal Product information

<Variations made to the Marketing Authorization Application do not affect information on the mechanism of action, pharmacological classification, claimed indications and recommendations for use of the medicinal product, as well as information on its specific pharmacology aspects.>

II.2 Overview on the submitted Marketing Authorization Application for the medicinal product

As of the date of the update of this assessment report on the safety, efficacy, and quality, the current version (sequence) of the marketing authorization application is 000n.

II.3. General comments on compliance with GMP, GLP, GCP, and harmonized ethical principles

<The variations made do not change the Marketing Authorization Application regarding to the information on compliance with GMP, GLP, GCP, and harmonized ethical principles.>

III. Scientific review and discussion

III.1. Quality aspects

<The variations made do not introduce any changes to the Marketing Authorization Application that may adversely affect the quality of the medicinal product.>

III.2. Non-clinical aspects

<No new information on non-clinical aspects of pharmacodynamics, pharmacokinetics and toxicology requiring a review of the ratio of expected benefit to possible risk of the medicinal product has been presented.>

III.3. Clinical aspects

<No new data on pharmacokinetics, pharmacodynamics, efficacy, clinical safety requiring a review of the ratio of expected benefit to possible risk of the medicinal product has been presented.>

<The variations made to the Marketing Authorization Application do not affect the information on the pharmacovigilance system master file of the Marketing Authorization Holder <name.>

<No risk management plan should be submitted.>

The marketing authorization holder shall submit periodic safety update reports for this medicinal product.>

IV. Risk-benefit assessment

<It has been established that the variations made do not introduce any changes to the Marketing Authorization Application that may affect the benefit-risk of the medicinal product.>

V. Recommended Conditions for Marketing Authorization and Product Information

V.1. Conditions of granting the Marketing Authorization

<There are no conditions or restrictions on the safe and effective use of the medicinal product.?

Legal status

Prescription status of the medicinal product: no prescription / prescription only / for medical and preventive treatment facilities

Follow-up measures

<Includes information on the commitments by the Applicant regarding the information contained in the marketing authorization application, which are subject to control by the Applicant and require making variations to the marketing authorization application in the post-approval period but not later than the planned re-approval of the medicinal product.

Special commitments

This section should specify the conditions for granting a marketing authorization (if applicable).

V.2. Summary of product characteristics

<The Marketing Authorization Holder has proposed the following changes to the SmPC:>

Or

<The variations made to the Marketing Authorization suggest no revision of the information contained in the SmPC.>

V.3. Patient leaflet (package leaflet) and user testing

V.3.1 Patient leaflet (package leaflet)

<The Marketing Authorization Holder has proposed the following changes to the PL:>

Or

<The variations made to the Marketing Authorization suggest no revision of the information contained in the SmPC.>

V.3.2. Evaluation of user testing

<The result of the user testing evaluation shall be presented.

Or

<No submission of the results of user testing of the patient leaflet is required.

There was no evaluation of the PL user testing. The Applicant has provided in the Marketing Authorization Application a sufficient justification regarding the absence of the need for user testing, recognized as acceptable by the reference Member State.>

V.4. Labeling and packaging mock-ups

<The results of assessment of compliance with the requirements of acts of the Union's bodies in the circulation of medicinal products are submitted.

Or

<No submission of new packaging mock-ups is required. The variations made to the Marketing Authorization do not affect the labeling information on the packs of the medicinal products for human use.>

VI. Conclusion

Based on the results of data expert examination on safety, efficacy, and quality and benefit-risk of the medicinal product under the Application No. _____ dated _____, *it is advised* / *not advised* to approve human use of the medicinal product in accordance with the procedure established by the Rules for Marketing Authorization and Expert Examination of Medicinal Products for Human Use approved by Decision No. 78 of the Eurasian Economic Commission's Council dated November 3, 2016.

_____